Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
Nucala (mepolizumab) gains FDA approval for two new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinject...
Read more -
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion re...
Read more -
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
Shingrix is a recombinant subunit adjuvanted vaccine given intramuscularly in two doses.
Read more -
GSK changes sales representative incentive programme
We are announcing changes to our incentive programme for sales representatives in certain countries.
Read more -
GSK’s strong science prominent at ATS 2019
More than 70 GSK abstracts presented
Read more -
Update on Consumer Healthcare Joint Venture with Pfizer
GlaxoSmithKline plc (LSE/NYSE: GSK) today has announced that the shareholder resolution relating to the transaction between GSK and Pfizer Inc to create a Consumer Healthcare Jo...
Read more -
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
-
Read more -
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
Read more -
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV.
Read more -
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dolutegravir + lamivudine compared to a traditional dolutegravir-based, three-d...
Read more -
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above
FDA approval marks the first medicine in the US approved for children with systemic lupus erythematosus (SLE)
Read more -
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
Dovato strengthens ViiV Healthcare’s industry-leading portfolio of innovative treatment approaches for people living with HIV.
Read more -
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca, the first complete 2-drug regimen, for the treatment of virologically suppressed adults with HIV
Read more -
GSK publishes product sales reporting changes and the impact of IFRS 16 ‘Leases’
GSK keeps its financial reporting under regular review to ensure that it remains current and in line with both the latest regulatory requirements and developing best practice wi...
Read more -
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma
Median progression-free survival extends to twelve months.
Read more -
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentation of data from the Phase 1/2 GARNET study
Read more -
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection
Comprehensive data from ATLAS and FLAIR studies presented today at the 2019 Conference on Retroviruses and Opportunistic Infections show investigational long-acting injectable t...
Read more -
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
Positive opinion issued by CHMP for intravenous zanamivir for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediat...
Read more -
GSK delivers sales, earnings and cash flow growth in 2018
Total EPS 73.7p, +>100% AER, +>100% CER; Adjusted EPS 119.4p +7% AER, +12% CER
Read more -
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
GlaxoSmithKline plc (LSE/NYSE: GSK) and Merck KGaA, Darmstadt, Germany today announced that they have entered into a global strategic alliance to jointly develop and commerciali...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
